Healthcare Realty Trust Inc (HR) Stock News

Whirlpool stock declined 1.13% to $28.83 while broader markets gained, underperforming the S&P 500's 0.6% rise. The company has lost 18.75% over the past month. Earnings forecasts show significant declines with EPS expected down 51.67% year-over-year and full-year earnings projected down 63.88%. Whirlpool holds a Zacks Rank of #5 (Strong Sell) with unchanged consensus estimates over the last 30 days.

C.H. Robinson Worldwide (CHRW) has a mean analyst price target of $199, suggesting 34.5% upside potential from its current price of $147.96. While price targets should be viewed with skepticism, the stock benefits from strong analyst agreement on positive earnings estimate revisions and holds a Zacks Rank #2 (Buy) rating, indicating potential near-term upside.

Whirlpool stock declined 2.32% to $30.67, underperforming the S&P 500's 0.17% loss. The appliance maker has dropped 23.12% over the past month, significantly worse than its sector's 8.3% decline. Earnings projections show a 51.67% EPS decrease and 1.07% revenue decline for the upcoming quarter, with full-year earnings expected to fall 63.88%. Despite these headwinds, Whirlpool maintains a Zacks Rank #2 (Buy) rating and trades at a Forward P/E discount to its industry average.

Palantir Technologies and Coherent Corp are both positioned in the AI and data infrastructure space, but Palantir emerges as the better investment choice. Palantir demonstrates stronger commercial AI momentum with 83% projected sales growth and 115% EPS growth, exceptional margins above 60%, and robust free cash flow generation. While Coherent offers more attractive valuation and benefits from AI datacenter demand, it faces higher risks from hyperscaler spending cycles and manufacturing execution. Palantir holds a Zacks Rank #1 (Strong Buy) versus Coherent's Rank #2 (Buy).

Novo Nordisk has entered into an exclusive license agreement with Hengrui Pharma for HRS-1596, a phase 1-ready once-weekly oral GLP-1/GIP dual receptor agonist. The deal is valued at up to $2.6 billion, including a $300 million upfront payment, with Novo obtaining global rights excluding mainland China, Hong Kong, Macao, and Taiwan. The drug targets obesity, type 2 diabetes, and other metabolic diseases.

Archer Aviation (ACHR) and Textron (TXT) are both advancing next-generation aviation technologies including electric aircraft and autonomous flight systems. However, Textron is favored as the better investment choice due to stronger earnings growth outlook (6.56% vs -52.38%), more attractive valuation (P/B of 1.7 vs 2.18), lower debt-to-capital ratio (32.09% vs 6.15%), and better recent stock performance (-3.3% vs -10.5% decline).

While Wall Street analysts have a bullish average brokerage recommendation (ABR) of 2.00 (Buy) for Archer Aviation with 40% Strong Buy ratings, the article cautions that brokerage recommendations often suffer from positive bias due to institutional vested interests. The company's Zacks Rank of #3 (Hold) based on unchanged earnings estimates suggests investors should be cautious despite the Buy-equivalent ABR, as earnings estimate revisions are a more reliable predictor of stock performance than analyst recommendations.

Aehr Test Systems (AEHR) has surged 363% in 2026 driven by AI semiconductor testing demand, but now trades at 18.59X forward sales—over 3x its historical median. While the company has strong backlog ($100.6M) and positive analyst sentiment, the elevated valuation leaves minimal margin for error. Key risks include heavy customer concentration (70% from top 5 customers), execution challenges, and semiconductor spending cyclicality. The stock carries a Zacks Rank #3 (Hold) rating.

Five Below's Chief Human Resources Officer Maureen Gellerman sold 1,610 shares (15% of her stake) for approximately $401,000 on September 9, 2026. Despite the sale, the insider retained 8,804 shares worth $2.1 million, indicating continued confidence in the company. The sale appears routine given Five Below's strong performance, with 73% stock returns over the past 12 months and robust Q2 2026 earnings showing 22.9% net sales growth.

In a comparison of two Medical Services stocks, Elevance Health (ELV) emerges as the superior value option over Danaher (DHR). ELV holds a Zacks Rank of #2 (Buy) with a Value grade of A, featuring a forward P/E of 15.70 and PEG ratio of 2.22. DHR has a Zacks Rank of #3 (Hold) with a Value grade of D, with a forward P/E of 23.84 and PEG ratio of 2.53. Based on valuation metrics and earnings outlook, ELV is positioned as the better value investment.

Whirlpool stock declined 3.44% to $34.00, outpacing broader market losses. The company has fallen 14.89% over the past month, significantly underperforming the S&P 500. Earnings projections show a 51.67% EPS decline for the upcoming quarter and a 63.88% full-year earnings decline, though revenue is expected to decline only modestly. The stock holds a Zacks Rank of #3 (Hold) with a Forward P/E of 15.65, in line with industry averages.

Aehr Test Systems has dramatically diversified its revenue streams, with AI processors and silicon photonics now driving nearly 95% of fiscal 2026 revenues, compared to over 95% EV-related SiC exposure two years prior. The company secured a $22 million follow-on order for AI processor systems in August and maintains a $100.6 million backlog with a $130-$150 million fiscal 2027 revenue outlook, though it faces intense competition from larger rivals Teradyne and FormFactor in the semiconductor test equipment market.

In a comparison of two automotive stocks, Gentherm (THRM) emerges as the superior value opportunity compared to Ferrari (RACE). THRM holds a Zacks Rank #1 (Strong Buy) with a Value grade of A, supported by a forward P/E of 13.29 and PEG ratio of 0.89. RACE, rated #3 (Hold) with a Value grade of D, has a forward P/E of 36.85 and PEG ratio of 3.54, indicating significantly higher valuations.

In a comparison of two Transportation-Services stocks, TFI International Inc. (TFII) emerges as the better value opportunity compared to C.H. Robinson Worldwide (CHRW). TFII holds a Zacks Rank of #2 (Buy) with a Value grade of B, featuring a lower forward P/E ratio of 22.64 and a PEG ratio of 0.85. CHRW has a Zacks Rank of #3 (Hold) with a Value grade of C, showing a higher forward P/E of 23.88 and PEG ratio of 1.25. TFII's superior valuation metrics and stronger earnings estimate revisions make it the preferred choice for value investors.

The article discusses various investment opportunities across sectors including robotics and AI, oil and natural gas, aerospace, employment trends, and biotech. It highlights earnings estimate increases for an oil and gas company, market cap movements for a space company, job growth in leisure and hospitality, and provides stock screening tools for investors seeking diversified exposure to emerging themes.

Archer Aviation (ACHR) has an average brokerage recommendation of 2.00 (Buy) with 4 Strong Buy and 2 Buy ratings from 10 firms. However, the article cautions that brokerage recommendations often carry positive bias due to institutional vested interests. The company's Zacks Rank #2 (Buy) rating is supported by a 1.9% increase in consensus earnings estimates over the past month, though the company is expected to report negative earnings of -$0.96 per share.

Coherent Corp. is projected to deliver strong fiscal 2027 revenue growth of 50.1% and earnings growth of 67.2%, driven by AI-optics demand. However, the stock trades at a premium 26.5X forward earnings with rising capital expenditures and weakening operating cash flow, creating execution risks. While earnings estimates are rising favorably, valuation and cash-flow pressures present concerns for investors.

Coherent Corp. shares declined 17% over the past month despite fiscal 2026 revenues rising 22.5% to $7.12 billion, driven by strong AI datacenter and communications demand. While the company shows robust demand visibility through 2028 and improving margins, investors are concerned about elevated execution risks from massive capital expenditures ($1.1B in fiscal 2026), declining operating cash flow, and overlapping product ramps. The stock trades at 26.5X forward earnings, above industry average, creating valuation concerns despite strong momentum.

United Therapeutics announced FDA acceptance of a supplemental new drug application for nebulized Tyvaso to treat idiopathic pulmonary fibrosis (IPF), with a regulatory decision expected in late April 2027. The TETON phase III studies demonstrated statistically significant improvements in lung function, including a 111.8 mL FVC benefit, reduced clinical worsening, and favorable secondary endpoints. If approved, Tyvaso would be the first FDA-approved inhaled anti-fibrotic treatment for IPF.

Phreesia reported Q3 2026 earnings of $0.03 per share, missing consensus estimates of $0.11 by 72.73%, though revenues slightly missed expectations at $129.46M. The stock has underperformed the S&P 500 by 41.5% year-to-date. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market near-term.

Whirlpool reported a wider-than-expected Q2 2026 loss of 21 cents per share and missed sales estimates, with net sales declining 6.8% year-over-year to $3,517 million. The company faced significant headwinds from lower volumes, retailer inventory pressure, tariffs, raw-material inflation, and fuel costs, causing gross margins to contract 360 basis points. Whirlpool lowered its full-year 2026 guidance for both GAAP and ongoing earnings, though it expects structural cost-reduction initiatives to generate over $150 million in savings. The stock has declined 15% since the earnings report and carries a Zacks Rank #3 (Hold) rating.

Archer Aviation (ACHR) shares have gained 14.9% over the past month, driven by its AEG partnership for an L.A. LIVE vertiport, selection in the eVTOL Integration Pilot Program, and expansion of its U.S. commercialization strategy. However, the company faces significant challenges including substantial losses ($480.9M in H1 2026), certification hurdles, and production execution risks before generating significant aircraft revenues. The stock trades at a discount valuation with strong liquidity, but new investors may want to wait for a more favorable entry point.

Whirlpool (WHR) fell 7.1% in the latest trading session, underperforming the broader market. The company faces significant headwinds with projected EPS down 51.67% for the upcoming quarter and full-year earnings expected to decline 63.88% year-over-year. Despite outperforming its sector over the past month, the stock carries a Zacks Rank #3 (Hold) rating with consensus estimates revised downward by 30.77% over the past month.

IBM has completed its acquisition of HRL Laboratories to expand its quantum computing capabilities by integrating silicon-spin qubits with its superconducting approach. The deal adds expertise in quantum sensing, materials science, and manufacturing. IBM expects its Quantum Starling system to perform 100 million quantum operations by 2029, with a next-generation Blue Jay system targeted for the mid-2030s.

Coherent Corp. (COHR) and AppLovin Corporation (APP) are both high-growth AI-focused technology companies. Coherent, which supports AI infrastructure through optical networking, shows stronger earnings momentum and faster expected growth (50% sales, 67% EPS) with a more attractive valuation. AppLovin's AI-powered advertising platform delivers superior margins and cash generation but faces downward earnings revisions and a richer valuation. Coherent receives a Zacks Rank #2 (Buy) while AppLovin holds Rank #3 (Hold).

Hormel Foods reported $2.96 billion in revenue for Q3 2026, missing analyst expectations of $3.05 billion by 2.81%. While EPS of $0.37 slightly beat estimates of $0.36, the company faced headwinds across most segments with retail sales down 4.3% and international sales declining 4.7% year-over-year. The stock has underperformed the broader market, declining 8.1% over the past month.

HR Chief is launching the CXO Summit on 7-8 October 2026 in London, a flagship event for Chief Human Resources Officers and senior HR executives. The summit features three panel discussions covering workforce transformation, skills development, and AI-ready workforce strategies, with confirmed speakers from NHS England, SUEZ, WPP, Shoosmiths, and Virgin Unite. The event aims to connect HR leadership with cross-functional C-suite executives across multiple sectors.

Celcuity announced FDA approval of REVTORPYK (gedatolisib), the first pan-PI3K and mTORC1/2 inhibitor, for treating HR+/HER2- locally advanced or metastatic breast cancer without PIK3CA mutations. In the Phase 3 VIKTORIA-1 trial, the drug reduced disease progression or death risk by 76% when combined with palbociclib and fulvestrant, and 67% with fulvestrant alone. Commercial launch is anticipated in late Q3 2026.

ANI Pharmaceuticals reported positive Phase 4 trial results for ILUVIEN (fluocinolone acetonide intravitreal implant) in treating chronic non-infectious uveitis affecting the posterior segment. The trial met both co-primary endpoints with statistically significant improvements in visual acuity (+3.6 letters) and central subfield thickness reduction (-157.5 microns) at 6 months. Safety profile was consistent with prior trials, with ocular hypertension (6%) and cataract (5%) as the most common adverse events.

Rosen Law Firm is reminding Phreesia, Inc. investors who purchased stock between May 8, 2025 and March 30, 2026 of the July 13, 2026 deadline to serve as lead plaintiff in a securities class action. The lawsuit alleges that Phreesia made false statements and concealed material facts regarding slowing demand and weakened pharmaceutical marketing commitments in its Network Solutions segment, resulting in investor damages.